Skip to main content
SpringerLink
Log in
Book cover

Anticoagulation pp 16–37Cite as

Antithrombotic drugs

  • Chapter

Abstract

Thromboembolic diseases are major cause of global mortality. Thrombosis genesis can be induced by endothelial injury, hyperviscosity and fibrinolysis decrease. The anatomic origin of thrombosis disorders differs according to diverse types of pathophysiology.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agnelli G, Cosmi B, DI Filippo. A randomised, double blind-placebo controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 67, 203–208, 1992.

    PubMed  CAS  Google Scholar 

  2. Ashida S, Abiko Y. Inhibition of platelet aggregation by a new agent, ticlopidine. Thromb Heamost 40, 542–550, 1979.

    CAS  Google Scholar 

  3. Beaumont JL, Caen JP, Bernard J. Action hémorragique de l’acide acétylsalicylique au cours des maladies du sang. Bull Soc Méd Hôp Paris 71, 1087, 1985.

    Google Scholar 

  4. Bonne C, Martin B, Regnault F. Potentiation of antiaggregating prostaglandins by ticlopidine. Thromb Haemost 46, Abst 67, 1981.

    Google Scholar 

  5. Bourdon P, Jablonski JA, Chao BH, Maraganore JM. Structure—function relation-ships of hirulog peptide interactions with thrombin. FEBS Lett 294, 163–166, 1991.

    Article  PubMed  CAS  Google Scholar 

  6. Bruno J, Yang D, Taylor LA, Leamster G. Role of platelet cAMP and prostaglandin synthesis in platelet aggregation inhibition by ticlopidine hydrochloride. Thromb Heamost 46, Abst 194, 66, 1981.

    Google Scholar 

  7. Cade JF, Buchanan MR, Boneu B, Okleford P. A comparison of the antithrombotic and heamorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 35, 613–625, 1984.

    Article  PubMed  CAS  Google Scholar 

  8. Chang JY. The functionnal domain of hirudin a thrombin-specific inhibitor. FEBS Lett 25, 4622–4628, 1986.

    Google Scholar 

  9. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironnement of the platelet GPIIb/IIIa complex. J Clin Invest 76, 101, 1985.

    Article  PubMed  CAS  Google Scholar 

  10. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/lIIa receptor in an experimental animal model. Blood 68, 783–786, 1986.

    PubMed  CAS  Google Scholar 

  11. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelet produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 72, 325, 1983.

    Article  PubMed  CAS  Google Scholar 

  12. Czapek EE, Kwaan HC, Szczecinski M. The effect of sulfated polysaccharide on ATIII. J Lab Clin Med 95, 783–790, 1980.

    PubMed  CAS  Google Scholar 

  13. Ellis DJ, Roe RL, Bruno JJ, Crauston BJ, McSpadden MM. The effect of ticlopidine hydrochloride on bleeding time and platelet function in man. (ABST). Thromb Heamost 46, 1973, 1981.

    Google Scholar 

  14. Harker LA, Slichter SJ. Studies of platelets and fibrinogen kinetics in patients with prosthetic valves. N Engl J Med 283, 1302–1305, 1970.

    Article  PubMed  CAS  Google Scholar 

  15. Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave JP, Courtney M, Tolstoshev P, LECOCQ JP. Cloning and expression of cDNA coding for the anticoagulant hirudin from the bloodsucking leech. Proc Natl Acad Sei USA 83, 1084–1088, 1986.

    Article  CAS  Google Scholar 

  16. Haycraft JB. On the action of a secretion abtained from the medicinal leech on the coagulation of the blood. Proc R Soc Lond 36, 478–487, 1884.

    Google Scholar 

  17. Hemker HC, Frank HLL. The mechanism of action of oral anticoagulants and its consequences for the practice of oral anticoagulation. Heamostasis 15, 203–270, 1985.

    Google Scholar 

  18. Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelets activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 75, 399–406, 1990.

    PubMed  CAS  Google Scholar 

  19. Klöcking HP, Markwardt F. Pentosan polysulfate-induced release of plasminogen activator. Heamostasis 6, 370–374, 1977.

    Google Scholar 

  20. Lecompte TH, Kher A, Gaillard JL, Samama M. Pharmacologie des agents antiplaquettairesJ des Mal Vascu]aires 8, 3, 1983.

    CAS  Google Scholar 

  21. Lee H, Paton RC, Ruan C, Caen JP. The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets. Thromb Heamost 46, 590–592, 1981.

    CAS  Google Scholar 

  22. Lindahl U. Biosynthesis of heparin and heparan sulfate. Upsal. J Med Sei 82, 78–79, 1977.

    Article  CAS  Google Scholar 

  23. Mao SJT, Yates MT, Owen TJ, Krstenansky JL. Interaction of hirudin with thrombin: Identification of a minimal binding domain that inhibits clotting activity. Biochemistry 27, 8170–8173, 1988.

    Article  PubMed  CAS  Google Scholar 

  24. Maraganore JM, Bourdon P, Jablonski JA. Design and characterisation of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095–7101, 1990.

    Article  PubMed  CAS  Google Scholar 

  25. Maraganore JM, Chao BH, Joseph ML, et al. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 264, 8692–8698, 1989.

    PubMed  CAS  Google Scholar 

  26. Mardiguian J. Methods of preparation of low molecular weight heparins. Low Molecular Weight Heparins in Clinical Practice. Marcel Dekker Edit New-York, 7–12, 1992.

    Google Scholar 

  27. Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol 19, 924–932, 1970.

    Article  Google Scholar 

  28. Breckenbridge AM. Oral anticoagulant drugs. Sem Heamatol 15, 19–26, 1978.

    Google Scholar 

  29. Doutremepuich C, Lalanne MC, Doutremepuich F, Puyal C. Low molecular weight heparins today: Pharmacological considerations. In: Low Molecular Weight Heparins in Clinical Practice (C. Doutremepuich (Eds)). Marcel Dekker, New-York, pp 85–96 1992.

    Google Scholar 

  30. Johnson M, Heywood JB. Possible mode of action of ticlopidine: A novel inhibitor of platelet aggregation. Thromb Heamost 42, 367, 1979.

    CAS  Google Scholar 

  31. Nath N, Niewiarowski S, Joist JH. Platelet factor 4—antiheparin protein releasable from platelets: Purification and properties. J Lab Clin Med 82, 754–768, 1973.

    PubMed  CAS  Google Scholar 

  32. Topol EJ, Scarpace DG, Palabrica TM, Sutor RJ, Fox IH, Maraganore JM. Hirulog, a direct thrombin inhibitor peptide, instead of heparin for routine coronary angioplasty: pilot experience. Circulation (Supplement II), 84, Abstract 2354, 1991.

    Google Scholar 

  33. Rajah SM, Crow MJ, Ahmad R, Watson DA. The effect of dipyridamole on platelet function. Correlation with blood levels in man. Br J Clin Pharmacol 4, 129–133, 1977.

    CAS  Google Scholar 

  34. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombinheparin cofactor. J Biol Chem 248, 6490–6505, 1973.

    PubMed  CAS  Google Scholar 

  35. Scully MF, Kakkar W. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulfate (SP54). Thromb Res 36, 187–194, 1984.

    Article  PubMed  CAS  Google Scholar 

  36. Sie P, Ofosu F, Fernandez F, Buchanau MR, Petitou M, Bonneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Br J Haematol 64, J 707–714, 1986.

    Article  PubMed  CAS  Google Scholar 

  37. Soria C, Soria J, Ryckewaert JJ, Holmer E, Caen JP. Anticoagulant activities of pentosane polysulfate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 19, 455–463, 1980.

    Article  PubMed  CAS  Google Scholar 

  38. Talbot MD, Ambler J, Butler KD, Findlay VS, Peters RF, Tweed MF, Wallis RB. Recombinant desulfato-hirudin (CGP39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost 61, 77–80, 1989.

    PubMed  CAS  Google Scholar 

  39. Thomas DP, Marton RE, Barrowcliffe TW, Mulloy B, Johnson EA. Antifactor Xa activity of heparan sulfate., 14, 501–506, 1979.

    CAS  Google Scholar 

  40. Tollefsen DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258, 6713, 1983.

    PubMed  CAS  Google Scholar 

  41. Vairel EG. Heparins and fibrinolysis.In: Low Molecular Weight Heparins in Clinical Practice (C. Doutremepuich (Eds)). Marcel Dekker, New-York, pp 51–61, 1992.

    Google Scholar 

  42. Vairel EG, Brouty-Boye H, Toulemonde F, Doutremepuich C. Role de l’activité fibrinolytique indirecte des heparines et de composes voisins dans la prophylaxie des thromboses. Ann Pharma Franç 41, 339–353, 1983.

    CAS  Google Scholar 

Download references

Authors
  1. F. Azougagh Oualane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Doutremepuich
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Laboratoire d’Hematologie, 3, Place de la Victoire, 33076, Bordeaux cedex, France

    Christian Doutremepuich

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Oualane, F.A., Doutremepuich, F. (1994). Antithrombotic drugs. In: Doutremepuich, C. (eds) Anticoagulation. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2668-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2668-0_2

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7627-2

  • Online ISBN: 978-1-4612-2668-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation